IP Library › Granted Patent US 12,404,331
Granted Patent B2
US 12,404,331 · App. 17/604,555 · Granted Sep 2, 2025

Anti-PD-1 antibodies and uses thereof

Inventors: Wei-Wu He (Sugarland, TX); Paul Bryson (Alhambra, CA); Si Li (Alhambra, CA); Donghui Ma (North Potomac, MD)
Assignee: GUANGDONG TCRCURE BIOPHARMA TECHNOLOGY CO., LTD.
C07K16/2818A61K39/39A61K45/06A61K47/6849C07K2317/24C07K2317/565C07K2317/622C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,331
App. No.
17/604,555
Granted
Sep 2, 2025
Kind
B2
Abstract

This disclosure relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to PD-1 and block the interaction between PD-1 and PD-L1/PD-L2. The disclosure also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies, portions of fusion proteins or bispecific antibodies. Nucleic acid molecules encoding the antibodies, hybridomas, and methods for expressing antibodies are also provided. Pharmaceutical compositions comprising the antibodies are also provided. This disclosure also provides use of these antibodies to enhance T-cell function and upregulate cell-mediated immune responses for the treatment and prevention of various diseases.

Claims (53)

1. An antibody or antigen-binding fragment thereof that binds to PD-1

(Programed Cell Death Protein 1) comprising:

a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is % identical to a selected VH CDR3 amino acid sequence; and

a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is identical to a selected VL CDR3 amino acid sequence,

wherein the selected VH CDRs 1, 2, and 3 amino acid sequences and the selected VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:

(1) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 8, 9, 10, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 5, 6, 7, respectively;

(2) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 22, 23, 24, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 19, 20, 21, respectively;

(3) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 74, 75, 76, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 71, 72, 73, respectively; and

(4) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 34, 35, 36, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 31, 32, 33, respectively.

2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 8, 9, and 10, respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 5, 6, and 7, respectively.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 22, 23, and 24, respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 19, 20, and 21, respectively.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 74, 75, and 76, respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 71, 72, and 73, respectively.

5. The antibody or antigen-binding fragment thereof of claim 1 , wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 34, 35, and 36, respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 31, 32, and 33, respectively.

6. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment specifically binds to human PD-1.

7. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

8. The antibody or antigen-binding fragment thereof of claim 1 ,

wherein the antibody or antigen-binding fragment is a single-chain variable fragment (scFv) or a multi-specific antibody.

9. A nucleic acid comprising a polynucleotide encoding a polypeptide comprising:

(1) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 8, 9, and 10, respectively, and wherein the VH, when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 2 binds to PD-1;

(2) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 5, 6, and 7, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 4 binds to PD-1;

(3) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 22, 23, and 24, respectively, and wherein the VH, when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 16 binds to PD-1;

(4) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 19, 20, and 21, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 18 binds to PD-1;

(5) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 74, 75, and 76, respectively, and wherein the VH, when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 68 binds to PD-1;

(6) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 71, 72, and 73, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 70 binds to PD-1;

(7) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 34, 35, and 36, respectively, and wherein the VH, when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO: 28 binds to PD-1;

(8) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 31, 32, and 33, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 30 binds to PD-1;

(9) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 54, 55, and 56, respectively, and wherein the VH, when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO: 48 binds to PD-1;

(10) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 51, 52, and 53, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 50 binds to PD-1;

(11) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 64, 65, and 66, respectively, and wherein the VH, when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO: 58 binds to PD-1;

(12) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 61, 62, and 63, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 60 binds to PD-1;

(13) an immunoglobulin heavy chain or a fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 44, 45, and 46, respectively, and wherein the VH, when paired with a VL comprising the amino acid sequence set forth in SEQ ID NO: 38 binds to PD-1; or

(14) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 41, 42, and 43, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 40 binds to PD-1.

10. A vector comprising one or more of the nucleic acids of claim 9 .

11. A cell comprising one or more of the nucleic acids of claim 9 .

12. A method of producing an antibody or an antigen-binding fragment thereof, the method comprising

culturing the cell of claim 11 under conditions sufficient for the cell to produce the antibody or the antigen-binding fragment.

13. An antibody or antigen-binding fragment thereof that binds to PD-1 comprising a heavy chain variable region (VH) comprising SEQ ID NO: 4, 18, 30, 40, 50, 60, or 70, and a light chain variable region (VL) comprising SEQ ID NO: 2, 16, 28, 38, 48, 58 or 68.

14. The antibody or antigen-binding fragment thereof of claim 13 , wherein the VH comprises the sequence of SEQ ID NO: 4 and the VL comprises the sequence of SEQ ID NO: 2.

15. The antibody or antigen-binding fragment thereof of claim 13 , wherein the VH comprises the sequence of SEQ ID NO: 18 and the VL comprises the sequence of SEQ ID NO: 16.

16. The antibody or antigen-binding fragment thereof of claim 13 , wherein the VH comprises the sequence of SEQ ID NO: 70 and the VL comprises the sequence of SEQ ID NO: 68.

17. The antibody or antigen-binding fragment thereof of claim 13 , wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO: 28.

18. The antibody or antigen-binding fragment thereof of claim 13 , wherein the VH comprises the sequence of SEQ ID NO: 50 and the VL comprises the sequence of SEQ ID NO: 48.

19. The antibody or antigen-binding fragment thereof of claim 13 , wherein the VH comprises the sequence of SEQ ID NO: 60 and the VL comprises the sequence of SEQ ID NO: 58.

20. The antibody or antigen-binding fragment thereof of claim 13 , wherein the VH comprises the sequence of SEQ ID NO: 40 and the VL comprises the sequence of SEQ ID NO: 38.

21. An antibody or antigen-binding fragment thereof comprising VH CDRs 1, 2, 3, and VL CDRs 1, 2, 3 of an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) comprising SEQ ID NO: 4, 18, 30, 40, 50, 60, or 70, and a light chain variable region (VL) comprising SEQ ID NO: 2, 16, 28, 38, 48, 58 or 68.

22. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof of claim 1 covalently bound to a therapeutic agent.

23. A method of treating a subject having cancer, the method comprising administering a therapeutically effective amount of a composition comprising the antibody or antigen-binding fragment thereof of claim 1 , to the subject.

24. The method of claim 23 , wherein the subject has a solid tumor, a hematologic cancer, lymphoma, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, squamous cell lung cancer, renal cell carcinoma, cutaneous squamous cell carcinoma, urothelial carcinoma, merkel-cell carcinoma, or mesothelioma.

25. A method of decreasing the rate of tumor growth, the method comprising

contacting an immune cell with an effective amount of a composition comprising an antibody or antigen-binding fragment thereof of claim 1 , to the subject.

26. A method of killing a tumor cell, the method comprising contacting an immune cell with an effective amount of a composition comprising the antibody or antigen-binding fragment thereof of claim 1 , to the subject.

27. A method of treating or reducing the risk of developing an infectious disease, the method comprising administering a therapeutically effective amount of a composition comprising the antibody or antigen-binding fragment thereof of claim 1 , to the subject.

28. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2022
From: HE, WEI-WU; BRYSON, PAUL; LI, SI; MA, DONGHUI
To: TCRCURE BIOPHARMA CORP.
Reel/Frame 060257/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2022
From: TCRCURE BIOPHARMA CORP.
To: GUANGDONG TCRCURE BIOPHARMA TECHNOLOGY CO., LTD.; TCRCURE BIOPHARMA CORP.
Reel/Frame 060257/0412 →
Continuity (2)
Provisional Application 62836177 · Apr 19, 2019
Related Publication 20220195047A1 · Jun 23, 2022
References Cited (219)
US 4439196A · Higuchi · 1984 [cited by applicant]
US 4447224A · DeCant et al. · 1984 [cited by applicant]
US 4447233A · Mayfield · 1984 [cited by applicant]
US 4486194A · Ferrara · 1984 [cited by applicant]
US 4487603A · Harris · 1984 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4596556A · Morrow et al. · 1986 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4690915A · Rosenberg · 1987 [cited by applicant]
US 4790824A · Morrow et al. · 1988 [cited by applicant]
US 4941880A · Burns · 1990 [cited by applicant]
US 5064413A · McKinnon et al. · 1991 [cited by applicant]
US 5087616A · Myers et al. · 1992 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5312335A · McKinnon et al. · 1994 [cited by applicant]
US 5374548A · Caras · 1994 [cited by applicant]
US 5383851A · McKinnon et al. · 1995 [cited by applicant]
US 5399163A · Peterson et al. · 1995 [cited by applicant]
US 5399331A · Loughrey et al. · 1995 [cited by applicant]
US 5416016A · Low et al. · 1995 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5811097A · Allison et al. · 1998 [cited by applicant]
US 5837243A · Deo et al. · 1998 [cited by applicant]
US 5877293A · Adair et al. · 1999 [cited by applicant]
US 5886152A · Nakatani et al. · 1999 [cited by applicant]
US 5922845A · Deo et al. · 1999 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6451995B1 · Cheung et al. · 2002 [cited by applicant]
US 7446190B2 · Sadelain et al. · 2008 [cited by applicant]
US 7569664B2 · Karsten et al. · 2009 [cited by applicant]
US 8728474B2 · Honjo et al. · 2014 [cited by applicant]
US 9642906B2 · Ramos et al. · 2017 [cited by applicant]
US 9834606B2 · Li et al. · 2017 [cited by applicant]
US 10174098B2 · Hinrichs et al. · 2019 [cited by applicant]
US 11072658B2 · Fayadat-Dilman · 2021 [cited by examiner]
US 20020131960A1 · Sadelain et al. · 2002 [cited by applicant]
US 20030064477A1 · Band et al. · 2003 [cited by applicant]
US 20030170238A1 · Gruenberg et al. · 2003 [cited by applicant]
US 20110256154A1 · Vincent et al. · 2011 [cited by applicant]
US 20130149337A1 · Cooper et al. · 2013 [cited by applicant]
US 20130287748A1 · June · 2013 [cited by applicant]
US 20170044259A1 · Tipton et al. · 2017 [cited by applicant]
US 20170247454A1 · Benz et al. · 2017 [cited by applicant]
US 20180030137A1 · Eenennaam et al. · 2018 [cited by applicant]
US 20180185482A1 · Sheng et al. · 2018 [cited by applicant]
US 20180208896A1 · Poirot et al. · 2018 [cited by applicant]
US 20200046769A1 · Wang · 2020 [cited by applicant]
US 20230077100A1 · Zhao et al. · 2023 [cited by applicant]
CN 101213297 · 2008 [cited by applicant]
CN 105777906 · 2016 [cited by applicant]
CN 107043420 · 2017 [cited by applicant]
CN 107249605 · 2017 [cited by applicant]
CN 107325180 · 2017 [cited by applicant]
CN 107881185 · 2018 [cited by applicant]
CN 108135998 · 2018 [cited by applicant]
CN 110139873 · 2019 [cited by applicant]
CN 110423757 · 2019 [cited by applicant]
CN 110511960 · 2019 [cited by applicant]
EP 404097 · 1990 [cited by applicant]
IN 340060 · 2020 [cited by applicant]
WO WO1993011161 · 1993 [cited by applicant]
WO WO1996013593 · 1996 [cited by applicant]
WO WO1996018105 · 1996 [cited by applicant]
WO WO1996027011 · 1996 [cited by applicant]
WO WO1999018129 · 1999 [cited by applicant]
WO WO2004033685 · 2004 [cited by applicant]
WO WO2004076646 · 2004 [cited by applicant]
WO WO2006037960 · 2006 [cited by applicant]
WO WO2008077546 · 2008 [cited by applicant]
WO WO2008156712 · 2008 [cited by applicant]
WO WO2009114335 · 2009 [cited by applicant]
WO WO2010029434 · 2010 [cited by applicant]
WO WO2011044186 · 2011 [cited by applicant]
WO WO2014134165 · 2014 [cited by applicant]
WO WO2014140904 · 2014 [cited by applicant]
WO WO2016115274 · 2016 [cited by applicant]
WO WO2016081518 · 2016 [cited by applicant]
WO WO2016126608 · 2016 [cited by applicant]
WO WO2016196388 · 2016 [cited by applicant]
WO WO2017149515 · 2017 [cited by applicant]
WO WO2018067618 · 2018 [cited by applicant]
WO WO2018195348 · 2018 [cited by applicant]
WO WO2018197492 · 2018 [cited by applicant]
WO WO2019079777 · 2019 [cited by applicant]
WO WO2019195486 · 2019 [cited by applicant]
US 8,252,592 B2, 08/2012, Sadelain et al. (withdrawn) [cited by applicant]
Kwok, Gerry, et al. “Pembrolizumab (keytruda).” Human vaccines & immunotherapeutics 12.11 (2016): 2777-2789. (Year: 2016). [cited by examiner]
Kiyoshi, Masato, et al. “Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition state stabilizes the antibody-antigen complex.”… [cited by examiner]
Rudikoff, Stuart, et al. “Single amino acid substitution altering antigen-binding specificity.” Proceedings of the National Academy of Sciences 79.6 (1982): 1979-1983. (Year: 1982). [cited by examiner]
Sela-Culang, Inbal, Vered Kunik, and Yanay Ofran. “The structural basis of antibody-antigen recognition.” Frontiers in immunology 4 (2013): 302. (Year: 2013). [cited by examiner]
[No Author Listed] [online], “NCT02280811 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers,” clinicaltrials.gov, 2017, retrieved from URL <https://clinicaltrials.gov/ct2/show/NCT02280811>, 12… [cited by applicant]
Iwamura et al., “siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions,” Gene Therapy, 2012, 19:959-966. [cited by applicant]
Jin et al., “Engineered T cells targeting E7 mediate regression of human papillonnavirus cancers in a murine model,” JCI Insight, 2018, 3(8):e99488, 12 pages. [cited by applicant]
Li et al., “Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor—Modified T Cells Engineered to Secrete Checkpoint Inhibitors,” Clin Cancer Res, 2017, 23(22):6982-6992. [cited by applicant]
Rafiq et al., “Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade,” Blood, 2017, 130(Suppl 1): 842, 3 pages. [cited by applicant]
Ramos et al., “Human Papillomavirus Type 16 E6/E7-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies,” J Immunother., Jan. 2013, 36(1):66-76, 21 pages. [cited by applicant]
Rice et al., “An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression,” Cancer Gene Therapy, 2015, 22:454-462. [cited by applicant]
Suarez et al., “Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model,” Oncotarget, 2016, 7(23):34341-34355. [cited by applicant]
Yeku et al. “Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment,” Scientific reports, 2017, 7(1):1-14. [cited by applicant]
Doran et al., “T-cell receptor gene therapy for human papillomavirus—associated epithelial cancers: a first-in-human, phase I/II study,” Journal of Clinical Oncology, Oct. 2019, 37(30):2759-2768. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/CN2021/075388, mailed on Jul. 28, 2022, 6 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2020/074366, mailed on Nov. 9, 2020, 14 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2021/075388, mailed on May 6, 2021, 10 pages. [cited by applicant]
Liu et al., “Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers,” Current Oncology Reports, Dec. 2018, 20(12):1-11. [cited by applicant]
Nakagawa et al., “HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein,” Journal of Virology, Nov. 2006, 81(3):1412-1423. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/CN2020/074366, mailed on Aug. 18, 2022, 7 pages. [cited by applicant]
Topalian et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” The New England Journal of Medicine, Jun. 28, 2012, 366(26):2443-2454. [cited by applicant]
Wang et al., “Study on Preparation and Biological Function of Chicken PD-1 Monoclonal Antibody,” China Animal Husbandry & Veterinary Medicine, Dec. 7, 2018, 45(12):3363-3370 (English Abstract). [cited by applicant]
Abhinandan et al., “Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains,” Molecular Immunology, Aug. 2008, 45(14):3832-3839. [cited by applicant]
Agata et al., “Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes,” Int. Immunol., May 1, 1996, 8(5):765-772. [cited by applicant]
Bansal et al., “Human papillomavirus-associated cancers: A growing globalproblem,” International Journal of Applied and Basic Medical Research, 2016, 6(2):84-89. [cited by applicant]
Bennett et al., “Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses,” J.… [cited by applicant]
Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci., Jan. 1977, 66(1):1-19. [cited by applicant]
Bernard et al., “Proteasomal degradation of p53 by human papillomavirus E6 oncoproteinrelies on the structural integrity of p53 core 5 domain,” PloS one, 2011, 6(10):e25981, 10 pages. [cited by applicant]
Bird et al., “Single-Chain Antigen-Binding Proteins,” Science, Oct. 21, 1988, 242(4877):423-426. [cited by applicant]
Blank et al., “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,” Cancer Immunol. Immunother., 2005, 54:307-314. [cited by applicant]
Bloeman et al., “Adhesion molecules: a new target for immunoliposome-mediated drug delivery,” FEBS Lett., Jan. 3, 1995, 357(2):140-144. [cited by applicant]
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science, Jul. 5, 1985, 229(4708):81-83. [cited by applicant]
Brianti et al., “Review of HPV-related diseases and cancers,” New Microbiologica, 2017, 40(2):80-85. [cited by applicant]
Brown et al., “Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,” J. Immunol., Feb. 1, 2003, 170(3):1257-1266. [cited by applicant]
Carter et al., “PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2,” Eur. J. Immunol., Feb. 12, 2002, 32(3):634-643. [cited by applicant]
Castellsague, “Natural History And Epidemiology of Hpv Infection and Cervical Cancer,” Gynecologic Oncology, 2008, 110:S4-S7. [cited by applicant]
Chan et al., “Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination—Review of Current Perspectives,” Journal of Oncology, 2019, 3257939:1-11. [cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, Dec. 28, 1989, 342(6252):877-883. [cited by applicant]
Cox et al., “A Directory of Human Germ-line VH Segments Reveals a Strong Bias in their Usage,” Eur. J. Immunol., Apr. 1994, 24(4):827-836. [cited by applicant]
Creelan, “Update on immune checkpoint inhibitors in lung cancer,” Cancer Control, Jan. 1, 2014, 21(1):80-89. [cited by applicant]
Davila et al., “CD19 CAR-targeted T cells induce long20term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acutelymphoblastic leukemia,” PloS one, Apr. 9, 2013, 8(4):e61338, 14 pages. [cited by applicant]
Dong et al., “B7-H1 pathway and its role in the evasion of tumor immunity,” J. Mol. Med., Apr. 30, 2003, 81:281-287. [cited by applicant]
Dong et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,” Nat. Med., Jun. 24, 2002, 8:793-800. [cited by applicant]
Dranoff et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity,” Proc. Natl. Acad… [cited by applicant]
Draper et al., “Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6,” Clinical Cancer Research, 2015, 21(19):4431-4443. [cited by applicant]
Estep et al. “High throughput solution-based measurement of antibody-antigen affinity and epitope binning,” mAbs, Mar. 1, 2013, 5(2):270-278. [cited by applicant]
Freeman et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation,” J. Exp. Med., Oct. 2, 2000, 192(7):1027-1034. [cited by applicant]
Freeman et al., “Protect the killer: CTLs need defenses against the tumor,” Nat. Med., Aug. 1, 2002, 8:787-789. [cited by applicant]
GenBank Accession No. AJ406678, “ [cited by applicant]
GenBank Accession No. BC070333.1, “ [cited by applicant]
GenBank Accession No. NP_001107830.1, “Programmed cell death protein 1,” dated Nov. 13, 2017, 3 pages. [cited by applicant]
GenBank Accession No. NP_001271065.1, “Programmed cell death protein 1,” dated Apr. 24, 2016, 1 page. [cited by applicant]
GenBank Accession No. NP_032824.1, “Programmed cell death protein 1 precursor [Mus musculus],” dated Apr. 5, 2018, 3 pages. [cited by applicant]
GenBank Accession No. NT_024637, “ [cited by applicant]
Ghetie et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells,” Proc. Natl. Acad. Sci. USA, Jul. 8, 1997, 94(14):7509-7514. [cited by applicant]
Greenberg et al., “Deficient Cellular Immunity—Finding and Fixing the Defects,” Science, Jul. 23, 1999, 285:546-551. [cited by applicant]
Hahne et al., “Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape,” Science, Nov. 22, 1996, 274(5291):1363-1366. [cited by applicant]
He et al., “Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,” J. Immunol., Oct. 15, 2004, 173(8):4919-4928. [cited by applicant]
Hermans et al., “The Vital assay: a versatile fluorometric technique for assessing CTL-and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo,” Journal of Immunological Methods, Feb. 2004, 285(1):25… [cited by applicant]
Hirano et al., “Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,” Cancer Research, Feb. 2005, 65(3):1089-1096. [cited by applicant]
Holliger et al., ““Diabodies”: small bivalent and bispecific antibody fragments,” Proc. Natl. Acad. Sci. USA, Jul. 15, 1993, 90(14):6444-6448. [cited by applicant]
Howard et al., “Biological properties of interleukin 10,” Immunology Today, Jun. 1, 1992, 13(6):198-200. [cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Hutloff et al., “ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,” Nature, Jan. 21, 1999, 397:263-266. [cited by applicant]
International Preliminary Report in International Appln. No. PCT/US2019/46076, mail dated Feb. 25, 2021, 10 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/028773, dated Sep. 28, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2019/46076, dated Dec. 23, 2019, 17 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2020/028773, dated Sep. 29, 2020, 14 pages. [cited by applicant]
Irani et al., “Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases,” Molecular Immunology, Oct. 2015, 67(2):171-182. [cited by applicant]
Ito et al., “Effective Priming of Cytotoxic T Lymphocyte Precursors by Subcutaneous Administration of Peptide Antigens in Liposomes Accompanied by Anti-CD40 and Anti-CTLA-4 Antibodies,” Immunobiology, Apr. 2000, 201(5):… [cited by applicant]
Iwai et al., “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” Proc. Natl. Acad. Sci. USA, Sep. 17, 2002, 99(19):12293-12297. [cited by applicant]
Iwai et al., “PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells,” Int. Immunol., Feb. 2005, 17(2):133-144. [cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, May 29, 1986, 321:522-525. [cited by applicant]
Jones et al., “The INNs and outs of antibody nonproprietary names,” mAbs, 2016, 8(1):1-9. [cited by applicant]
Kehrl et al., “Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth,” J. Exp. Med., May 1, 1986, 163(5):1037-1050. [cited by applicant]
Keinanen et al., “Biosynthetic lipid-tagging of antibodies,” FEBS Lett., Jun. 6, 1994, 346:123-126. [cited by applicant]
Killion et al., “Systemic Targeting of Liposome-Encapsulated Immunomodulators to Macrophages for Treatment of Cancer Metastasis,” Immunomethods, Jun. 1994, 4(3):273-279. [cited by applicant]
Knudson et al., “M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine,” Oncoimmunology, 2018, 7(5):e1426519, 15 pages. [cited by applicant]
Kochenderfer et al., “Construction and pre-clinical evaluation of an anti-CD19 chimeric antigen receptor,” Journal of Immunotherapy, 2009, 32(7):689-702, 26 pages. [cited by applicant]
Kohler et al., “Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion,” Eur. J. Immunol. Jul. 1976, 6(7):511-9, 5 pages. [cited by applicant]
Kohler et al., “Pillars Article: Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, Aug. 7, 1975, 256(5517):495-497. [cited by applicant]
Konishi et al., “B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,” Clin. Cancer Res., Aug. 2004, 10(15):5094-5100. [cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes,” Immunol. Today, Mar. 1983, 4(3):72-79. [cited by applicant]
Kwok et al., “Pembrolizumab (Keytruda),” Human Vaccines and Immunotherapeutics, 2016, 12(11):2777-2789. [cited by applicant]
Latchman et al., “PD-L2 is a second ligand for PD-1 and inhibits T cell activation,” Nat. Immunol., Mar. 2001, 2:261-268. [cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Immunology, Jan. 2003, 27(1):55-77. [cited by applicant]
Mannarini et al., “Human Papilloma Virus (HPV) InHead and Neck Region: Review of Literature,” Acta Otorhinolaryngologica Italica, Jun. 2009, 29(3):119-126. [cited by applicant]
Martin et al., “Molecular modeling of antibody combining sites,” Methods Enzymol., Jan. 1, 1991, 203:121-153. [cited by applicant]
Martin, “Protein sequence and structure analysis of antibody variable domains,” Antibody Engineering, Springer Berlin Heidelberg, 2001, Chapter 31:422-439. [cited by applicant]
McLaughlin-Drubin et al., “Viruses Associated With Human Cancer,” Biochimica et Biophysica Acta., Mar. 2008, 1782(3):127-150. [cited by applicant]
Melero et al., “Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors,” Nature Medicine, Jun. 1, 1997, 3:682-685. [cited by applicant]
Mokyr et al., “Realization of the Therapeutic Potential of CTLA-4 Blockade in Low-Dose Chemotherapy-treated Tumor-bearing Mice,” Cancer Research, Dec. 1998, 58(23):5301-5304. [cited by applicant]
Moore et al., “Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein,” Journal of Virology, Mar. 1996, 70(3):1863-1872, 13 pages. [cited by applicant]
Morea et al., “Antibody structure, prediction and redesign,” Biophys. Chem., Oct. 1997, 68(1-3):9-16. [cited by applicant]
Morea et al., “Conformations of the third hypervariable region in the VH domain of immunoglobulins,” J. Mol. Biol., Jan. 16, 1998, 275(2):269-294. [cited by applicant]
Okazaki et al., “New regulatory co-receptors: inducible co-stimulator and PD-1,” Curr. Opin. Immunol., Dec. 2002, 14(6):779-782. [cited by applicant]
Owais et al., “Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice,” Antimicrob. Agents Chemother… [cited by applicant]
Ping et al., “T-cell receptor engineered T cells for cancer treatment: current status and future directions,” Protein & Cell, 2018, 9(3):254-266. [cited by applicant]
Poljak, “Production and structure of diabodies,” Structure, Dec. 1994, 2(12):1121-1123. [cited by applicant]
Ponomarenko et al., “Antibody-protein interactions: benchmark datasets and prediction tools evaluation,” BMC Structural Biology, Oct. 2, 2007, 7:64, 19 pages. [cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc. Natl. Acad. Sci. USA, Dec. 1, 1989, 86(24):10029-10033. [cited by applicant]
Raedler, “Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma,” American Health & Drug Benefits, Mar. 2015, 8:96-100. [cited by applicant]
Ranade, “Drug Delivery Systems. 1. Site-Specific Drug Delivery Using Liposomes as Carriers,” J. Clin. Pharmacol., Aug. 1989, 29:685-694. [cited by applicant]
Ridge et al., “A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell,” Nature, Jun. 4, 1998, 393:474-478. [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” Nature, Mar. 24, 1998, 332:323-327. [cited by applicant]
Rosenberg, “Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know,” Nature Reviews Clinical Oncology, Aug. 2, 2011, 8(10):577-585. [cited by applicant]
Schreier et al., “Targeting of liposomes to cells expressing CD4 using glycosylphosphatidylinositol-anchored gp120. Influence of liposome composition on intracellular trafficking,” J. Biol. Chem., Mar. 1994, 269(12):909… [cited by applicant]
Silva et al. “The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation,” Journal of Biological Ch… [cited by applicant]
Simon et al., “CAR-T cell therapy in melanoma: A future success story,” Experimental Dermatology, Oct. 4, 2018, 27(12):1315-1321. [cited by applicant]
Songsivilai et al., “Bispecific antibody: a tool for diagnosis and treatment of disease,” Clin. Exp. Immunol., Mar. 1990, 79:315-321. [cited by applicant]
Stanley et al., “HPV: From Infection to Cancer,” Biochemical Society Transactions, Nov. 23, 2007, 35(6):1456-1460. [cited by applicant]
Themeli et al., “Generation of tumor-targeted humanT lymphocytes from induced pluripotent stem cells for cancer therapy,” Nature Biotechnology, Aug. 11, 2013, 31(10):928-933, 8 pages. [cited by applicant]
Thomas, “Of ITAMs and ITIMs: turning on and off the B cell antigen receptor,” J. Exp. Med., Jun. 1, 1995, 181(6):1953-1956. [cited by applicant]
Tomlinson et al. “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VHSegments with Different Hypervariable Loops,” J. Mol. Biol., Oct. 5, 1992, 227(3):776-798. [cited by applicant]
Topalian et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” New England Journal of Medicine, Jun. 28, 2012, 366(26):2443-2454. [cited by applicant]
Tsukahara et al., “CD 19 target-engineered T-cells accumulate at tumor lesionsin human B-cell lymphoma xenograft mouse models,” Biochemical and Biophysical Research Communications, 2013, 438(1):84-89. [cited by applicant]
Umezawa et al., “Liposome targeting to mouse brain: Mannose as a recognition marker,” Biochem. Biophys. Res. Commun., Jun. 30, 1988, 153(3):1038-1044. [cited by applicant]
Vidarsson et al., “IgG subclasses and allotypes: from structure to effector functions,” Frontiers in Immunology, Oct. 20, 2014, 5(520):1-17. [cited by applicant]
Vivier et al., “Immunoreceptor tyrosine-based inhibition motifs,” Immunol. Today, Jun. 1997, 18(6):286-291. [cited by applicant]
Wadhwa et al., “Receptor mediated glycotargeting,” Journal of Drug Targeting, 1995, 3(2):111-127. [cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Weinberg et al., “Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity,” J. Immunol., Feb. 15, 2000, 164(4):2160-2169. [cited by applicant]
Wolff et al., “Monoclonal antibody homodimers: enhanced antitumor activity in nude mice,” Cancer Research, Jun. 1993, 53(11):2560-2565. [cited by applicant]
Wu et al., “An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity,” J. Exp. Med., Aug. 1, 1970, 132(2):211-250. [cited by applicant]
Zapata et al., “Engineering linear F(ab')2 fragments for efficient production in [cited by applicant]
Zhao et al., “Enhancing tumor targeting and apoptosis using non-covalent antibody homo-dimers,” J. Immunol., Sep. 2002, 25(5):396-404. [cited by applicant]
Zur Hausen et al., “Human Papilloma Viruses,” Annu. Rev. Microbiol., 1994, 48:427-447. [cited by applicant]
EP Search Report in European Appln. No. 19850035.7, dated Jun. 14, 2022, 9 pages. [cited by applicant]
Tang et al., “Original Article—The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1 + cancer therapy,” Am J Transl Res, Jan. 1, 2015, pp. 460-473. [cited by applicant]